Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

PerkinElmer acquires autoimmune testing firm Euroimmun for $1.3 billion

Deal to boost PerkinElmer's growth by adding leading positions in autoimmune & allergy diagnostics

BS B2B Bureau  |  Waltham, Massachusetts (USA) 

Diagnostics

Analytical & supplier Inc has entered into a definitive agreement to acquire Medical Laboratory AG for $ 1.3 billion. 

Based in Lubeck, Germany, with approximately 2,400 employees, is widely recognised as a global leader in and an emerging force in infectious disease and testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. is expected to generate approximately $310 million in revenue this year, and over the last five years, the company has averaged revenue growth of 19 percent. In 2016, the company generated sales in more than 130 countries worldwide, with approximately 45 percent of revenues in China, 30 percent in Europe, Middle East & Africa, 5 percent in the Americas and 20 percent in Rest of World. 

The acquisition combines two innovative, results-driven cultures with a shared mission of improving global health. The combination expands PerkinElmer's reach into autoimmune and diagnostic markets, while offering new infectious disease capabilities to customers in China. In addition, as a market leader in the US for reproductive health, will have the opportunity to drive Euroimmun's solutions into this well-established channel. 

“With the acquisition of and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world. We look forward to working with the team as we partner together to help improve global health through advanced diagnostics,” said Robert Friel, chairman and chief executive officer of

PerkinElmer's comprehensive global portfolio will now include solutions focused on: reproductive health; autoimmune, infectious disease and testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. 

RECOMMENDED FOR YOU

PerkinElmer acquires autoimmune testing firm Euroimmun for $1.3 billion

Deal to boost PerkinElmer's growth by adding leading positions in autoimmune & allergy diagnostics

Deal to boost PerkinElmer's growth by adding leading positions in autoimmune & allergy diagnostics
Analytical & supplier Inc has entered into a definitive agreement to acquire Medical Laboratory AG for $ 1.3 billion. 

Based in Lubeck, Germany, with approximately 2,400 employees, is widely recognised as a global leader in and an emerging force in infectious disease and testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. is expected to generate approximately $310 million in revenue this year, and over the last five years, the company has averaged revenue growth of 19 percent. In 2016, the company generated sales in more than 130 countries worldwide, with approximately 45 percent of revenues in China, 30 percent in Europe, Middle East & Africa, 5 percent in the Americas and 20 percent in Rest of World. 

The acquisition combines two innovative, results-driven cultures with a shared mission of improving global health. The combination expands PerkinElmer's reach into autoimmune and diagnostic markets, while offering new infectious disease capabilities to customers in China. In addition, as a market leader in the US for reproductive health, will have the opportunity to drive Euroimmun's solutions into this well-established channel. 

“With the acquisition of and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world. We look forward to working with the team as we partner together to help improve global health through advanced diagnostics,” said Robert Friel, chairman and chief executive officer of

PerkinElmer's comprehensive global portfolio will now include solutions focused on: reproductive health; autoimmune, infectious disease and testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. 

image
Business Standard
177 22

PerkinElmer acquires autoimmune testing firm Euroimmun for $1.3 billion

Deal to boost PerkinElmer's growth by adding leading positions in autoimmune & allergy diagnostics

Analytical & supplier Inc has entered into a definitive agreement to acquire Medical Laboratory AG for $ 1.3 billion. 

Based in Lubeck, Germany, with approximately 2,400 employees, is widely recognised as a global leader in and an emerging force in infectious disease and testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. is expected to generate approximately $310 million in revenue this year, and over the last five years, the company has averaged revenue growth of 19 percent. In 2016, the company generated sales in more than 130 countries worldwide, with approximately 45 percent of revenues in China, 30 percent in Europe, Middle East & Africa, 5 percent in the Americas and 20 percent in Rest of World. 

The acquisition combines two innovative, results-driven cultures with a shared mission of improving global health. The combination expands PerkinElmer's reach into autoimmune and diagnostic markets, while offering new infectious disease capabilities to customers in China. In addition, as a market leader in the US for reproductive health, will have the opportunity to drive Euroimmun's solutions into this well-established channel. 

“With the acquisition of and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world. We look forward to working with the team as we partner together to help improve global health through advanced diagnostics,” said Robert Friel, chairman and chief executive officer of

PerkinElmer's comprehensive global portfolio will now include solutions focused on: reproductive health; autoimmune, infectious disease and testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. 

image
Business Standard
177 22